Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oleiferoside H is a novel triterpenoid saponin isolated from the ethanol extract of the roots of *Camellia oleifera*. Chemically, it is characterized as an oleanane-type saponin with sugar moieties attached at the C-3 position of the aglycone. Research into this compound, along with related oleiferosides, has focused on its potential antineoplastic properties. In vitro studies using the MTT assay have evaluated its cytotoxic activity against various human tumor cell lines, including lung cancer (A549), melanoma (B16), hepatocellular carcinoma (BEL-7402), and breast cancer (MCF-7). While other members of the series (such as oleiferoside C) have shown potent activity, oleiferoside H is typically characterized as having moderate to weak cytotoxic effects in these preclinical models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oleiferoside H.